Application of NADH and/or NADPH in antiallergic drugs and/or antiallergic health products

A technology of anti-allergic and health care products, which is applied in the direction of drug combination, allergic diseases, and pharmaceutical formulas. It can solve problems such as adverse reactions, allergies requiring repeated medication, and easy recurrence, and achieve the effect of alleviating allergic symptoms

Inactive Publication Date: 2019-09-06
HOBOOMLIFE BIO TECH SHENZHEN CO LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In view of this, the present invention provides the application of NADH and/or NADPH anti-allergic drugs and/or anti-allergic health care products, which are u...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of NADH and/or NADPH in antiallergic drugs and/or antiallergic health products
  • Application of NADH and/or NADPH in antiallergic drugs and/or antiallergic health products
  • Application of NADH and/or NADPH in antiallergic drugs and/or antiallergic health products

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] In this example, C3H / HeJ peanut-allergic mice were prepared by the following method: 6-week-old female C3H / HeJ mice were purchased from Shanghai Experimental Animal Center. The test animals are reared under specific non-pathogenic conditions in a room with an average temperature of 21° C. to 23° C. and a relative humidity of 40% to 70%, with a 12-hour light / dark cycle.

[0037] The mice in the sensitization group were gavaged with peanut homogenate (single 80mg / each) every day, and on the 21st day after the implementation of the sensitization measures, the mice were given intraperitoneal injection (i.p) injection of 30mg CPE (peanut extract) / hour Rats, and young rats that had never been exposed to peanuts served as negative controls. Then, by skin testing and anaphylaxis (by measuring vascular leak, monitoring clinical symptoms, rectal temperature, respiratory rate, and measuring serum mast cell protease-1 (mmcp-1) - a specific marker of mast cell degranulation) The assa...

Embodiment 2

[0057] C3H / HeJ peanut-allergic mice in the test example of the present invention were prepared by the following method: 6-week-old female C3H / HeJ mice were purchased from Shanghai Experimental Animal Center. The test animals were reared under specific non-pathogenic conditions in a room with an average temperature of 21°C-23°C and a relative humidity of 40%-70%, with a 12-hour light / dark cycle.

[0058] The mice in the sensitization group were gavaged with peanut homogenate (single 80mg / each) every day, and on the 21st day after the implementation of the sensitization measures, the mice were given intraperitoneal injection (i.p) injection of 30mg CPE (peanut extract) / hour Rats, and young rats that had never been exposed to peanuts served as negative controls. This is followed by skin testing and detection of anaphylaxis (by measuring vascular leak, monitoring clinical symptoms, rectal temperature, respiratory rate, and measuring serum mast cell protease-1 (mmcp-1) - a specific...

Embodiment 3

[0078] 3.1 Experimental materials and experimental reagents:

[0079] The peripheral blood of healthy children of the same age and the peripheral blood (PBMC) of children with food allergy were obtained from Shenzhen Children's Hospital. IL10, TGF-β, IFN-γ and IgE antibodies (purchased from Sigma-aldrich), NADH (self-prepared). 3.2 Experimental method

[0080] The peripheral blood (PBMC) of healthy children and food-allergic children were randomly collected, and the PBMC were suspended in a medium (RPMI-1640; Mediatech) with 10% autologous plasma, and incubated at 37°C, 5% CO 2 The culture groups in the cell culture incubator are as follows:

[0081] ①. Healthy group: PBMC (10^7 / ml) of healthy children were suspended in culture medium (adding physiological saline 0.2 mg / ml to the medium;

[0082] ②. Blank group: PBMC (10^7 / ml) from children with food allergy were suspended in culture medium (0.2 mg / ml of normal saline was added to the medium);

[0083] ③. Treatment group 1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of research and development of medicines and health products, and particularly relates to an application of NADH and/or NADPH in antiallergic drugs and/or antiallergic health products. The present invention provides the application of NADH and/or NADPH in the antiallergic drugs and/or the antiallergic health products. In the present invention, NADH/NADPH can be administrated to induce Treg cells to secrete immunosuppressive cytokines IL10, TGF-beta and the like. which can inhibit the immune response of TH2, blood basophilia and tissue mast cells, reduces sIgEsynthesis, and increases sIgG and sIgA synthesis, and alleviates allergy symptoms; can stimulate the allergen-specific TH1 response, produces cytokines IFN-gamma and TGF-gamma, inhibits the immune response of TH2, blood basophilia and tissue mast cells, reduces sIgE synthesis and increases sIgG and sIgA synthesis, and alleviates allergy symptoms. The application solves the technical defects thatthe anti-allergic drugs have some adverse reactions, need repeated medication and allergic recurrence, and provides a long-acting, immunomodulatory natural anti-allergic drug or health care product.

Description

technical field [0001] The invention belongs to the field of research and development of medicines and health products, and in particular relates to the application of NADH and / or NADPH in anti-allergic drugs and / or anti-allergic health products. Background technique [0002] Allergy is a series of hypersensitivity reactions caused by the human body's exposure to some allergens in the environment that have little impact on ordinary people, that is, the human body's excessive immunity to certain exogenous substances. Allergies include: immediate anaphylaxis (also known as IgE-mediated anaphylaxis), antibody-dependent and cytotoxic anaphylaxis, immune complex-mediated anaphylaxis, and delayed anaphylaxis. [0003] In the prior art, common anti-allergic drugs include: antihistamines, glucocorticoids, anti-leukotriene drugs, intranasal decongestants, etc. These drugs all have certain adverse reactions, and repeated medication is required to control symptoms. Allergies are prone...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7084A61P37/08A61P11/06A61P11/02A61P1/02
CPCA61K31/7084A61P1/02A61P11/02A61P11/06A61P37/08A61K2300/00
Inventor 陈建生
Owner HOBOOMLIFE BIO TECH SHENZHEN CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products